Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16442868 | 0.92 | FFAR1 (0.41) | PPARGFFAR1FFAR4MGLLLMNA | |
| SCHEMBL18022751 | 0.91 | NTRK1 (0.38) | PPARGMGLLLMNANTRK1IGF1R | |
| SCHEMBL16442879 | 0.90 | SLC22A12 (0.36) | SLC22A12PPARGFFAR1FFAR4LMNA | |
| SCHEMBL16683840 | 0.90 | LMNA (0.41) | SLC22A12PPARGMGLLLMNATSHR | |
| SCHEMBL16442821 | 0.90 | NPC1 (0.40) | PPARGLMNAMAPK1NR1H4 | |
| SCHEMBL16442829 | 0.86 | PPARG (0.39) | SLC22A12PPARGFFAR1FFAR4TSHR | |
| SCHEMBL17806103 | 0.86 | ALDH1A1 (0.39) | PPARGFFAR1FFAR4TSHRMAPK1 | |
| SCHEMBL17614538 | 0.86 | SLC22A12 (0.41) | SLC22A12LMNACYP3A4CYP2C9 | |
| SCHEMBL16442830 | 0.85 | PPARG (0.36) | PPARGFFAR1FFAR4HTT | |
| SCHEMBL16442831 | 0.85 | NPBWR1 (0.37) | PPARGFFAR1FFAR4LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9635857-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MRPS17, TAOK1, TAOK3 | SLC22A12 3165/4885PPARG 2461/4885FFAR1 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.